Kairos Pharma Ltd., a clinical-stage biopharmaceutical company, has announced positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) for patients with metastatic castration-resistant prostate cancer. The interim safety analysis revealed that the CD105 antagonist, when combined with standard hormone therapy apalutamide, was well tolerated by the first ten patients enrolled in the study. No dose-limiting toxicities or unexpected adverse events were reported, and treatment-related side effects were manageable. No Grade 3 or 4 toxicities were observed. The trial, which aims to enroll 100 patients, is currently accruing participants at multiple locations including Cedars-Sinai Medical Center. Interim efficacy data is expected in September 2025. Kairos Pharma is planning to discuss the design of a potential pivotal Phase 3 study with regulatory agencies based on emerging data.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.